The Bard PowerPort infection lawsuit reached a pivotal moment in May 2026 when the first bellwether trial in the multidistrict litigation concluded with a split outcome — a defense win on most claims but a deadlocked jury on the critical design-defect question. For the thousands of patients who suffered serious infections, catheter fractures, blood clots, and sepsis after receiving a Bard PowerPort implantable port, this verdict is neither a final answer nor a closed door. With 3,564 cases now pending in MDL 3081 in the District of Arizona and five more bellwether trials scheduled through February 2027, the litigation is entering its most consequential phase yet.
What Happened in Cook v. Becton, Dickinson & Co. — The May 2026 Bellwether Verdict
The first bellwether trial in the Bard PowerPort infection lawsuit MDL, Cook v. Becton, Dickinson & Co., concluded in May 2026 with a verdict that sent mixed signals to both sides. The jury rejected the plaintiff’s failure-to-warn, negligence, and consumer-fraud claims, handing Bard a defense victory on those counts. However, jurors deadlocked on the design-defect claim — the most legally significant allegation in the entire litigation — leaving that central question unresolved and opening the door to a potential retrial.
Plaintiff Cook alleged that a Bard PowerPort implanted in August 2022 caused a serious infection within just two weeks of the procedure. The infection required emergency removal of the device and placement of a PICC line to maintain vascular access. Despite the severity of the outcome, the jury found that the plaintiff’s infection was not caused by the device according to the evidence presented on the non-deadlocked counts. The plaintiff’s legal team has since moved for a new trial, arguing that the unresolved design-defect claim warrants a fresh proceeding before a new jury.
At the core of the design-defect allegations is the PowerPort’s material composition. Plaintiffs contend that the device’s ChronoFlex polyurethane combined with barium sulfate degrades over time, creating a roughened surface that facilitates microbial growth and biofilm formation. This alleged material degradation, the plaintiffs argue, makes the device unreasonably dangerous and prone to causing catheter fracture, infection, thrombosis, and life-threatening sepsis. You can review the MDL court docket and related federal case filings on Justia for detailed procedural records from MDL 3081.
Key Statistics: MDL 3081 Bard PowerPort Litigation at a Glance
The scale of the Bard PowerPort infection lawsuit litigation has grown substantially through 2026. The table below summarizes the most critical data points shaping this case as of July 2026.
| Metric | Detail | Source / Date |
|---|---|---|
| Total cases pending in MDL 3081 | 3,564 filings | District of Arizona, May 2026 |
| First bellwether trial outcome | Defense win (failure-to-warn, negligence, fraud); hung jury on design defect | Cook v. BD, May 2026 |
| FDA MAUDE blood clot reports (Dec 2025–Feb 2026) | 122 adverse event reports | FDA MAUDE Database, 2026 |
| FDA MAUDE embolism reports (Dec 2025–Feb 2026) | 17 adverse event reports | FDA MAUDE Database, 2026 |
| Typical MDL medical device settlement range | $500,000–$2,000,000+ | Product Liability Benchmarks, 2026 |
| Average jury verdict (product liability, 2026) | $7,000,000+ | Product Liability Benchmarks, 2026 |
| Next bellwether trials scheduled | July 7, Aug 18, Oct 13, Dec 1, 2026; Feb 2, 2027 | MDL 3081 Scheduling Order, 2026 |
| Global settlement reached | No | MDL 3081, as of July 2026 |
The Centers for Disease Control and Prevention maintains data on healthcare-associated infections, including catheter-related bloodstream infections, which are directly relevant to the types of harm alleged by PowerPort plaintiffs.
FDA Adverse Event Data and the Concealment Allegations
One of the most damaging allegations in the Bard PowerPort infection lawsuit is that Becton, Dickinson & Co. concealed known dangers from patients and physicians despite accumulating adverse event reports in the FDA’s MAUDE (Manufacturer and User Facility Device Experience) database. Between December 2025 and February 2026 alone, MAUDE records reflect 122 reports of blood clots and 17 reports of embolism associated with PowerPort devices — a volume that plaintiffs argue should have triggered more aggressive labeling warnings and potentially a product recall or redesign.
The broader adverse event record allegedly includes more than 400 reports during a relevant period cited in plaintiff filings. Plaintiffs contend that Bard had knowledge of the ChronoFlex polyurethane degradation problem and the associated infection and thrombosis risks but failed to adequately communicate these dangers to the medical community or update device labeling to reflect the true risk profile. The jury’s deadlock on design defect — rather than a clear plaintiff verdict — suggests these material science arguments require further development before the next panel.
How Material Degradation Allegedly Causes Harm
According to expert testimony in the Cook trial and related plaintiff filings, the combination of ChronoFlex polyurethane and barium sulfate creates a material that is particularly vulnerable to surface degradation in biological environments. As the catheter material breaks down, the surface becomes irregular and porous at a microscopic level, creating an ideal substrate for bacterial biofilm formation. Once a biofilm establishes itself on the catheter surface, it becomes extremely difficult to eradicate with antibiotics alone, frequently necessitating emergency device removal. The downstream consequences — serious systemic infection, sepsis, clot formation, and pulmonary embolism — can be life-altering or fatal. Cornell Law School’s Legal Information Institute provides a thorough overview of products liability law, including the design-defect doctrine central to these claims.
What the Hung Jury Means for Settlement Leverage and Future Trials
In mass tort MDL litigation, bellwether trials serve a specific strategic function: they provide real-world data on how juries respond to the evidence, enabling both sides to calibrate the financial risk of continued litigation versus global settlement. The May 2026 outcome in Cook is inherently ambiguous. The defense victory on failure-to-warn and negligence claims is significant — it suggests that Bard’s warning-label strategy may survive jury scrutiny — but the deadlock on design defect means the most valuable claim in the litigation remains alive and unresolved.
For plaintiffs with serious injuries — including hospitalization, sepsis, catheter fracture requiring surgery, or long-term vascular damage — individual jury verdicts can dramatically exceed pre-trial settlement offers. Product liability jury verdicts in 2026 average above $7 million for serious injury cases, while MDL settlements for medical device cases typically range from $500,000 to $2 million or more depending on injury severity. Plaintiffs evaluating their options may find it useful to consult a personal injury settlement calculator to develop an initial estimate of potential case value based on medical costs, lost income, and pain and suffering.
The Road Ahead: Five More Bellwether Trials Through 2027
The MDL schedule is aggressive. With bellwether trials set for July 7, August 18, October 13, and December 1, 2026, and a fifth scheduled for February 2, 2027, the court is clearly pushing toward a resolution that will either catalyze a global settlement or force Bard to defend hundreds of individual cases. Each trial result — win, loss, or hung jury — adds to the data set that both plaintiff attorneys and Bard’s insurers use to model aggregate liability. A plaintiff win on design defect in any of the upcoming trials would materially shift the settlement calculus in favor of the thousands of injury victims still waiting for compensation. No class action has been certified, and no global settlement has been announced as of July 2026.
Who Qualifies to File a Bard PowerPort Infection Lawsuit
Individuals who received a Bard PowerPort implantable port — also sold under the PowerPort isp, SlimPort, and related brand names — and subsequently experienced serious complications may have viable claims. The types of injuries most commonly alleged in the Bard PowerPort infection lawsuit MDL include catheter-related bloodstream infection (CRBSI), catheter fracture or embolization, deep vein thrombosis (DVT), pulmonary embolism, sepsis, and emergency surgical intervention for device removal. The strength of any individual claim depends heavily on the timing of complications relative to implantation, the documentation of medical treatment, and the severity and permanence of the resulting harm.
Statutes of limitations vary by state and can be as short as two years from the date of injury discovery. Nolo’s guide to personal injury statutes of limitations provides state-by-state information that can help potential plaintiffs understand their filing deadlines. Missing the statute of limitations almost always results in permanent loss of the right to seek compensation, making timely legal consultation essential for anyone who has suffered PowerPort-related complications.
Documenting Your PowerPort Injury Claim
Strong documentation is the foundation of any successful Bard PowerPort infection lawsuit. Injured patients and their families should gather complete medical records showing the device implantation, any complications and hospitalizations, all treatments received (including antibiotics, surgical removal, PICC line placement, or other interventions), and documentation of ongoing health consequences. Records of lost wages, out-of-pocket medical expenses, and expert opinions regarding causation all strengthen a claim’s settlement and trial value. Plaintiffs whose injuries resulted in the death of a family member may also explore wrongful death remedies under applicable state law.
Frequently Asked Questions About the Bard PowerPort Infection Lawsuit
What is the current status of the Bard PowerPort MDL as of July 2026?
As of July 2026, MDL 3081 in the District of Arizona has 3,564 active cases. The first bellwether trial, Cook v. Becton, Dickinson & Co., concluded in May 2026 with a defense verdict on failure-to-warn and negligence but a hung jury on design defect. The plaintiff has moved for a new trial. Five additional bellwether trials are scheduled through February 2027. No global settlement has been reached.
What injuries are linked to the Bard PowerPort device?
Plaintiffs in the Bard PowerPort infection lawsuit allege that the device’s ChronoFlex polyurethane and barium sulfate material degrades over time, facilitating bacterial biofilm formation and microbial growth. Reported injuries include catheter-related bloodstream infections, catheter fracture and embolization, deep vein thrombosis, pulmonary embolism, sepsis, and emergency surgical removal of the device. FDA MAUDE data from December 2025 through February 2026 includes 122 blood clot reports and 17 embolism reports linked to PowerPort devices.
Does the Cook verdict mean Bard won the litigation?
No. The Cook verdict is a mixed result. While the jury sided with Bard on failure-to-warn, negligence, and consumer-fraud claims, jurors were unable to reach a verdict on the design-defect claim — the most significant allegation in the MDL. A hung jury means neither side prevailed on that count, and the plaintiff’s motion for a new trial keeps the issue alive. With four more bellwether trials scheduled in 2026 alone, the overall litigation outcome remains highly uncertain.
How much compensation could a Bard PowerPort victim receive?
Compensation amounts depend heavily on injury severity, duration of medical treatment, lost income, and long-term health consequences. Medical device MDL settlements typically range from $500,000 to $2 million or more for serious injuries. Product liability jury verdicts in 2026 average above $7 million for significant harm cases. There is no global settlement in place, so individual case values will be shaped by the results of upcoming bellwether trials. Consulting a personal injury settlement calculator can help injured patients develop a preliminary estimate of potential compensation.
What is the deadline to file a Bard PowerPort infection lawsuit?
Filing deadlines depend on the statute of limitations in your state, which typically ranges from one to four years from the date you discovered or should have discovered your injury. Because MDL 3081 is in an active phase and new cases are still being accepted, time is critical. Missing the statute of limitations will permanently bar your legal claim regardless of how serious your injuries are. Anyone who received a Bard PowerPort implant and experienced serious complications should seek legal consultation immediately to protect their right to file.
This content is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction regarding your specific legal situation.
Related reading: Operating Room Boom Collapse Verdict: $38.4 Million Award For Surgical Technologist Injuries From Defective Hillrom Equipment
Related reading: Hydrogen Sulfide Warehouse Fire Contamination Verdict: How Courts Value Airborne Chemical Exposure Injuries
Related reading: Cartiva Toe Implant Failure Damages: What Failed Synthetic Cartilage Devices Cost Patients
Related reading: ARC Automotive Airbag Inflator Defect Settlement 2026: What The MDL Reveals About Your Claim
Thomas B. Harrison is a personal injury legal consultant with extensive experience connecting injury victims with qualified attorneys across the United States. He specializes in helping people understand when they need legal representation and how to find the right personal injury attorney for their specific situation. Thomas is not an attorney and the information he provides is for educational purposes only.